Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF

Jean-Pierre Bassand*, Gabriele Accetta, Alan John Camm, Frank Cools, David A. Fitzmaurice, Keith A. A. Fox, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gloria Kayani, Lorenzo G. Mantovani, Frank Misselwitz, Hugo ten Cate, Alexander G. G. Turpie, Freek W. A. Verheugt, Ajay K. Kakkar

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

146 Citations (Web of Science)

Abstract

The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA(2)DS(2)-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. . Unique identifier: NCT01090362.
Original languageEnglish
Pages (from-to)2882-2889A
JournalEuropean Heart Journal
Volume37
Issue number38
DOIs
Publication statusPublished - 7 Oct 2016

Keywords

  • Atrial fibrillation
  • Anticoagulation
  • Stroke prevention
  • Stroke
  • Bleeding

Cite this